HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders.

Abstract
The aim of this review was to discuss an overview of type 2 diabetes; biology of PTP1B; role of PTP1B in metabolic disorders; and recent updates in the development of PTP1B inhibitors reported in literature since 1994. In this study, extensive literature search was carried out on PTP1B inhibitors of natural as well as synthetic origin in various scientific databases and research articles related to discovery of PTP1B inhibitors were selected for this study. Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for several human diseases including type 2 diabetes, obesity and cancer because of its seminal part as a negative modulator in both insulin and leptin signaling pathways. A large number of molecules of broad chemical diversity were reported as potent and selective PTP1B inhibitors over other protein tyrosine phosphatases. Several of these molecules have shown their potential in the treatment of various human diseases including type 2 diabetes, obesity, inflammation and cancer in various animal models. But only a very limited number of PTP1B inhibitors (including ertiprotafib, trodusquemine and JTT-551) has entered clinical trials and are finally withdrawn owing to their unsatisfactory effectiveness and undesirable adverse effects. Consequently, it is still highly imperative and of great importance to develop potent, highly selective and safe PTP1B inhibitors.
AuthorsSukhbir Singh, Ajmer Singh Grewal, Rupanshi Grover, Neelam Sharma, Bhawna Chopra, Ashwani Kumar Dhingra, Sandeep Arora, Sonika Redhu, Viney Lather
JournalBioorganic chemistry (Bioorg Chem) Vol. 121 Pg. 105626 (04 2022) ISSN: 1090-2120 [Electronic] United States
PMID35255350 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2022 Elsevier Inc. All rights reserved.
Chemical References
  • Enzyme Inhibitors
  • Insulin
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
Topics
  • Animals
  • Diabetes Mellitus, Type 2 (drug therapy, metabolism)
  • Enzyme Inhibitors (chemistry, pharmacology, therapeutic use)
  • Insulin
  • Obesity (drug therapy, metabolism)
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: